First‐line chemotherapy in advanced intra‐abdominal well‐differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. Issue 15 (13th May 2022)

• Record Type: Journal Article
• Authors: Stacchiotti, Silvia; Van der Graaf, Winette T. A.; Sanfilippo, Roberta G.; Marreaud, Sandrine I.; Van Houdt, Winan J.; Judson, Ian R.; Gronchi, Alessandro; Gelderblom, Hans; Litiere, Saskia; Kasper, Bernd
• Is Part Of: Cancer. Volume 128:Issue 15(2022)
• Page Start: 2932
• Page End: 2938
• Publication Date: 2022-05-13
• Subjects: anthracycline -- chemotherapy -- doxorubicin -- epirubicin -- ifosfamide -- liposarcoma -- sarcoma; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.34264
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: No prospective trial with anthracycline‐based chemotherapy has individually assessed response in a well‐differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first‐line chemotherapy in liposarcoma of intra‐abdominal origin (IA‐LPS) in patients who had entered the European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) trials. METHODS: We searched for all adult patients treated with first‐line chemotherapy for advanced IA‐LPS in the EORTC STBSG phase 2 and 3 trials from 1978. Treatment was aggregated into 5 groups: anthracycline alone, ifosfamide alone, doxorubicin plus ifosfamide (D+IFO), doxorubicin/cyclophosphamide/vincristine/dacarbazine, and "other" (brostallicin, trabectedin). Response was assessed prospectively by Response Evaluation Criteria in Solid Tumors or World Health Organization criteria. Progression‐free survival (PFS) and overall survival (OS) were computed by Kaplan‐Meier method. RESULTS: A total of 109 patients with IA‐LPS from 13 trials were identified (104 evaluable for response). Overall, there were 10/109 (9.2%) responders: 3/48 (6.3%) in the anthracycline alone group, 2/15 (13%) in the ifosfamide alone group, and 4/18 (22%) in the D+IFO group. At the 10‐month median follow‐up (interquartile range, 6‐24), the median OS was 19 months (95% CI, 15‐21) and median PFS 4 months (95% CI, 3‐6). D+IFO achieved a not statistically significant longer median PFS (12 months) and median OS (31 months) than observed with other regimens. Univariate/multivariate analysis did not identify prognostic factors. CONCLUSIONS: Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA‐LPS. Ifosfamide‐containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma.;